ARK2N Knockout Jurkat Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the Jurkat T-lymphocyte line, engineered to disrupt the ARK2N gene. This loss-of-function model enables investigation of ARK2N-mediated regulation of actin cytoskeleton dynamics and cell migration without a predetermined clonal background. The polyclonal population reflects heterogeneous gene disruption events, providing a robust tool for studying the collective impact of ARK2N deficiency in a leukemic T-cell background.
The parental Jurkat cell line is an immortalized human CD4+ T lymphocyte model originally isolated from an acute T cell leukemia patient. Its well-characterized T-cell receptor (TCR) signaling makes it extensively used to dissect signaling pathways governing activation, proliferation, and cytoskeletal rearrangements. The leukemic origin also provides a relevant platform for cancer biology, particularly hematopoietic malignancies.
ARK2N is a p53-responsive protein that directly binds the Arp2/3 complex, interacting with subunits ARPC2 and ARPC3 to regulate actin nucleation and branching. Transcriptionally activated by TP53, it modulates lamellipodia assembly and cell migration. Additionally, ARK2N has been implicated in p53-dependent suppression of cell proliferation. Upstream, Rho GTPases including Rac1 and Cdc42, along with the WAVE complex, converge on Arp2/3 to orchestrate actin polymerization. Within this network, ARK2N acts downstream of p53 and Rho GTPases to fine-tune Arp2/3 activity, influencing actin-based motility and potentially metastatic behavior.
In Jurkat T-cells, ARK2N disruption allows study of the intersection between tumor suppressor pathways and cytoskeletal organization. T-cells rely on dynamic actin remodeling for immune synapse formation, migration, and transendothelial trafficking. Dysregulation of these processes contributes to leukemogenesis and metastasis. The polyclonal knockout enables assessment of ARK2N loss on Jurkat motility, lamellipodia dynamics, and proliferation without clonal selection bias, offering insights into p53-mediated growth suppression and actin-dependent migration in leukemia-derived cells.
This ARK2N knockout model supports diverse experimental approaches. Gene disruption can be confirmed by Western blotting and RT-qPCR, while co-immunoprecipitation assays probe ARK2N-Arp2/3 interactions. Functional assays include Transwell migration and invasion to evaluate motility, immunofluorescence for F-actin to visualize cytoskeletal organization, and proliferation assays to assess growth suppression. Flow cytometry monitors T-cell markers to maintain leukemic phenotype. These applications facilitate research into actin dynamics, p53 signaling, and cancer metastasis, supporting therapeutic target validation. Contact Ascent Research for further details.
